Investigation of the Metabolism, Excretion and Pharmacokinetics of an Openlabel Single Dose of 300 mg [14C]Volasertib Administered Intravenously in Patients With Various Solid Tumours With a Possible Extension Phase With Nonlabelled Drug
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Volasertib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 15 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.